Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1992-07-30
1994-01-18
Rollins, John W.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
514934, A61K 3578
Patent
active
052798275
ABSTRACT:
A compound for the treatment of calcium oxalate kidney stone disease and viral infections caused by enveloped viruses which can be extracted and purified from leaves of the plant Eriobotrya japonica is disclosed. The compound has the following characteristics: inhibits calcium oxalate crystal growth in vitro; inhibits renal calcium oxalate crystal deposition in rats which are fed ethylene glycol, causes rats which are fed ethylene glycol and said compound to excrete less oxalate in their urine as compared to rats which are fed ethylene glycol without said compound; shows little or no loss in activity when exposed to an aqueous solution of pH 1.5 for 14 hours; shows increased activity when exposed to an aqueous solution of pH 12.7 for 15 hours; is polyanionic; is stable when heated in an aqueous solution (at pH of extract) at 98.degree. C. for 3 hours; water-soluble; insoluble in heptane, hexane, chloroform/methanol mix, diethyl ether, and ethanol/aqueous mix; binds to DEAE-A-25 Sephadex at pH 8.6; is eluted from the DEAE-A-25 Sephadex with 2M NaCl; and prevents cytopathogenicity of enveloped viruses such as herpes simplex virus. The present invention is also directed to a method for the treatment of calcium oxalate stone disease wherein the compound is administered, preferably for a prolonged period of time, to a patient suffering from or prone to calcium oxalate stone disease. The present invention is also directed to a method for the treatment of viral infection.
REFERENCES:
patent: 4264463 (1981-04-01), Kotake et al.
patent: 4336397 (1982-06-01), Cragoe, Jr. et al.
patent: 4337258 (1982-06-01), Rooney et al.
patent: 4399003 (1983-08-01), Sarig et al.
patent: 4421652 (1984-02-01), Cragoe, Jr. et al.
patent: 4423063 (1983-12-01), Rooney et al.
patent: 4428956 (1984-01-01), Cragoe, Jr. et al.
patent: 4431660 (1984-02-01), Cragoe, Jr. et al.
patent: 4597952 (1986-07-01), Fabre et al.
patent: 4689322 (1987-08-01), Kulbe et al.
patent: 4804476 (1989-02-01), Sinkovitz et al.
patent: 5137722 (1992-08-01), Costello
Strohmaier et al., "Excretion of glycosaminoglycans (GAG) . . . D-glucosamine", pp. 205-210.
Martelli et al., "Multisulphated dermatan as a GAG . . . calcium oxalate stone formation", pp. 197-203.
Danielson et al., "Glycosaminoglycans as inhibitors . . . clinical practice", pp. 193-195.
"Inhibitors of Crystallization . . . Clinical Application", Proc. of the Int'l. Mtg. held in Bologna, Sep. 7-9 (1987), pp. 271-282.
Ashan et al., Journal of Ethnopharmacology, vol. 26, pp. 249-254 (1989).
Jianzhong, Journal of Traditional Chinese Medicine, 2(3), pp. 187-194 (1982).
Fellstrom et al., Clinical Science, vol. 71, pp. 61-64 (1986).
Brown et al., Urolithiasis and Related Clinical Research, pp. 891-894 (1985).
Schneider, "Medical Plant Agents . . . Recurrent Urolithiasis", p. 863 (1989).
Walenga et al., Seminars in Thrombosis and Hemostatsis, vol. 17, Supplement 2, pp. 137-142 (1991).
J. Costello et al., "Activity of Phospholipase A.sub.2 in Plasma . . . ", Clinical Chemistry, vol. 36, No. 2, 1990, pp. 198-200.
G. Premecz et al., "Phospholipase C and phospholipase A.sub.2 . . . ", FEBS Letters, vol. 249, No. 2, pp. 257-260.
M. Baba et al., "Sulfated Polysaccharides Are Potent and . . . ", Antimicrobial Agents and Chemotherapy, Nov. 1988, pp. 1742-1745.
H. Mitsuya et al., "Dextran Sulfate Suppression of Viruses in . . . " Science, vol. 240, pp. 646-649.
D. Abrams et al., "Oral Dextran Sulfate (UA001) in the . . . " Annals of Internal Medicine, vol. 110, No. 3, pp. 183-188.
F. Defrise-Quertain et al., "Phospholipase inactivation induced by an . . . ", J. Pharm. Pharmac., 1978, vol. 30, pp. 608-612.
Allegheny-Singer Research Institute
Rollins John W.
LandOfFree
Extract and pharmaceutical composition for treatment of calcium does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Extract and pharmaceutical composition for treatment of calcium , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Extract and pharmaceutical composition for treatment of calcium will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1134980